ReviewCurrent treatment options in oncology2025
The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer.
Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stoma-Free Intersphincteric Resection in Low Rectal Cancer Without Radiotherapy: A Prospective Cohort Study on Safety and Recovery.Diseases of the colon and rectum · 2026Article
- Clinical progress and technological innovations in sphincter-preserving treatment for ultra-low rectal cancer.Frontiers in oncology · 2026Review
- Article
- Successful sphincter preservation and long-term survival in a patient with ultra-low locally advanced rectal cancer treated with photodynamic therapy combined with multimodal treatment: a case report and literature review.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementColorectal cancer is the third leading cause of cancer death worldwide. In China, the incidence and mortality of colorectal cancer are increasing, in which low rectal cancer is more common. Ultra-low rectal cancer refers to rectal cancer where the distance between the tumor and the anus is less than 5 cm, it accounts for about 70%-80% of rectal tumors. Intersphincteric resection (ISR), an important technical means for anal preservation of ultra-low rectal cancer, although could reduce the pain of patients during the surgical process, increase the anal preservation rate of patients and improve the life quality of patients, still has many adverse effects such as the high incidence of anorectal anastomotic leakage and high anterior resection syndrome. Many modified ISRs have emerged due to the limitations and adverse reactions of traditional ISR surgery. the purpose of this article is to review the progress of ISR surgery to improve its use in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.